✦ LIBER ✦

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)

✍ Scribed by Christoph Walz; Martin Sattler

Book ID: 108110062
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 388 KB
Volume: 57
Category: Article
ISSN: 1040-8428
DOI: 10.1016/j.critrevonc.2005.06.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

t(5;6;12) associated with resistance to

t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia

✍ Marija Denčić-Fekete; Vesna Đorđević; Clelia Tiziana Storlazzi; Gradimir Jankovi 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 310 KB

Granulocytic sarcoma giant in chronic my

Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy

✍ Rita de Cássia RosáRio Cavalheiro; Perla Vicari; Fernanda Maria Morselli; Lariss 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB 👁 2 views

Treatment modalities in hematology: Imat

Treatment modalities in hematology: Imatinib mesylate as therapy for chronic myeloid leukemia

✍ A. Gratwohl 📂 Article 📅 2002 🏛 Carden Jennings Publishing 🌐 English ⚖ 212 KB

Imatinib therapy in chronic myelogenous

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

✍ Hochhaus, A; La Rosée, P 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 187 KB

Mutational Analysis and Overcoming Imati

Mutational Analysis and Overcoming Imatinib Resistance in Chronic Myeloid Leukemia with Novel Tyrosine Kinase Inhibitors

✍ Michael J. Mauro 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 155 KB

Acute myeloid leukemia developing during

Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities

✍ Attaphol Pawarode; Sheila N.J. Sait; Alain Nganga; Lionel J. Coignet; Maurice Ba 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 171 KB

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been